|Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects.|
|PMID: 20736469 Owner: NLM Status: MEDLINE|
|CONTEXT: Herpes simplex and herpes zoster infections are common and often treated with antiviral drugs including acyclovir, valacyclovir, and famciclovir. Safety of these antivirals when used in the first trimester of pregnancy is insufficiently documented.
OBJECTIVE: To investigate associations between exposure to acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and risk of major birth defects.
DESIGN, SETTING, AND PARTICIPANTS: Population-based historical cohort study of 837,795 live-born infants in Denmark from January 1, 1996, to September 30, 2008. Participants had no diagnoses of chromosomal aberrations, genetic syndromes, birth defect syndromes with known causes, or congenital viral infections. Nationwide registries were used to ascertain individual-level information on dispensed antiviral drugs, birth defect diagnoses (categorized according to a standardized classification scheme), and potential confounders.
MAIN OUTCOME MEASURE: Prevalence odds ratios (PORs) of any major birth defect diagnosed within the first year of life by exposure to antiviral drugs.
RESULTS: Among 1804 pregnancies exposed to acyclovir, valacyclovir, or famciclovir in the first trimester, 40 infants (2.2%) were diagnosed with a major birth defect compared with 19,920 (2.4%) among the unexposed (adjusted POR, 0.89; 95% confidence interval [CI], 0.65-1.22). For individual antivirals, a major birth defect was diagnosed in 32 of 1561 infants (2.0%) with first-trimester exposure to acyclovir (adjusted POR, 0.82; 95% CI, 0.57-1.17) and in 7 of 229 infants (3.1%) with first-trimester exposure to valacyclovir (adjusted POR, 1.21; 95% CI, 0.56-2.62). Famciclovir exposure was uncommon (n = 26), with 1 infant (3.8%) diagnosed with a birth defect. Exploratory analyses revealed no associations between antiviral drug exposure and 13 different subgroups of birth defects, but the number of exposed cases in each subgroup was small.
CONCLUSION: In this large nationwide cohort, exposure to acyclovir or valacyclovir in the first trimester of pregnancy was not associated with an increased risk of major birth defects.
|Björn Pasternak; Anders Hviid|
Related Documents :
|12784299 - First-year mortality rates for selected birth defects, hawaii, 1986-1999.
2956519 - Maternal exposure to spermicides in relation to certain birth defects.
15670109 - Influence of prenatal diagnosis and pregnancy termination of fetuses with birth defects...
17159659 - Assessment of birth defects according to maternal therapy among infants in the women an...
15211709 - High rates of neural tube defects in ukraine.
10770089 - Neural tube defects in turkey: prevalence, distribution and risk factors.
16113149 - Eurocat: 25 years of european surveillance of congenital anomalies.
17054219 - Cysteine, cystine or n-acetylcysteine supplementation in parenterally fed neonates.
9145349 - A follow-up study of infants < or = 2000 g birthweight treated in central queensland.
|Type: Journal Article; Research Support, Non-U.S. Gov't|
|Title: JAMA Volume: 304 ISSN: 1538-3598 ISO Abbreviation: JAMA Publication Date: 2010 Aug|
|Created Date: 2010-08-25 Completed Date: 2010-08-27 Revised Date: 2014-09-17|
Medline Journal Info:
|Nlm Unique ID: 7501160 Medline TA: JAMA Country: United States|
|Languages: eng Pagination: 859-66 Citation Subset: AIM; IM|
|APA/MLA Format Download EndNote Download BibTex|
analogs & derivatives*,
Abnormalities, Drug-Induced / epidemiology*
Acyclovir / adverse effects*, analogs & derivatives*, therapeutic use
Antiviral Agents / adverse effects*, therapeutic use
Denmark / epidemiology
Herpes Simplex / drug therapy
Herpes Zoster / drug therapy
Pregnancy Trimester, First
Valine / adverse effects, analogs & derivatives*, therapeutic use
|0/Antiviral Agents; 104227-87-4/famciclovir; 452-06-2/2-Aminopurine; HG18B9YRS7/Valine; MZ1IW7Q79D/valacyclovir; X4HES1O11F/Acyclovir|
JAMA. 2010 Nov 24;304(20):2242-3; author reply 2243
Evid Based Med. 2011 Feb;16(1):30 [PMID: 21109680 ]
JAMA. 2010 Aug 25;304(8):905-6 [PMID: 20736478 ]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A piece of my mind. Hope.
Next Document: Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: ...